MedTrace Logo

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

NCT05595408 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2025-12-09

No results posted yet for this study

Summary

In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual disease (MRD) and early diagnosis of UTUC recurrence, and explored the role of ctDNA and utDNA detection of MRD in the prediction of adjuvant therapy efficacy and prognostic evaluation.

Conditions

  • Muscle Invasive Upper Tract Urothelial Carcinoma

Interventions

DRUG

Adjuvant chemotherapy

cisplatin/carboplatin-gemcitabine 4-6 cycles

DRUG

adjuvant immunotherapy

immunotherapy for one year

Sponsors & Collaborators

  • West China Hospital

    collaborator OTHER

  • RenJi Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2025-11-03
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05595408 on ClinicalTrials.gov